If orforglipron receives approval for obesity in April 2026, it will enter a market that Morgan Stanley estimates could reach $100 billion annually by the early 2030s, potentially transforming Eli Lilly's already dominant position in the metabolic disease space
It was demonstrated to have an LOD of 50 pg/mL based on recovery from 2 mL of urine
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis
Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School, said she doesnt support the use of compounded GLP-1 drugs but also worries that restrictions could add new strain to the overall supply
Let your doctor know if you are pregnant, planning to become pregnant, or breastfeeding, as semaglutide's effects in these situations are not fully known
Dagenais, G